ZYME
Zymeworks Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 2 ▲ Zymeworks reported strong 2025 financial results with 39% revenue gr…
- Apr 21 ▲ Zymeworks announced positive Phase 1 data for ZW191, an FRα-targetin…
- Jun 14 FDA: Zymeworks Presents New Phase 1 Data for Folate Receptor Al…
- Jun 29 ▲ Zymeworks Inc. (ZYME) announced an agreement to acquire Theravance B…
- Aug 5 HSR Early Termination: Zymeworks Inc.; Theravance…
- Aug 25 ▲ Zymeworks announced that its partner Jazz Pharmaceuticals received F…
- Sep 17 Wolfe Research initiates
- Sep 23 ▲ Zymeworks completed its acquisition of Theravance Biopharma, adding…
- Sep 28 ▲ Zymeworks completed its acquisition of Theravance Biopharma, adding…
- Oct 9 ▼ 1 insider sell $357.6K at $25.85
- Oct 23 ▲ Zymeworks entered into an exclusive global license and collaboration…
- Nov 9 ▲ Zymeworks reported Q3 2026 revenue of $256.5M (vs consensus $221.0M)…
- Nov 13 New insider trade: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersMIXED
1 insider sold $357.6K. Excludes 3 subscriber-only trades.
- InstitutionsMIXED
Q3 2026: 20 added (0 new), 14 trimmed or exited.
- AnalystsBULLISH
18 of 19 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate $2.100 → $2.185 over 90 days. 2 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest +6.0% to 5.91M shares. 4.3 days to cover, ≈8.4% of shares.
- TrendRANGE
4% below its 50-day average. New closing high $31.46 on Nov 10.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MORGAN STANLEY | ADD | $85.7M |
| Fisher Asset Management, LLC | DOUBLED | $16.1M |
| DIMENSIONAL FUND ADVISORS LP | TRIM | $14.1M |
| FEDERATED HERMES, INC. | ADD | $6.5M |
| Jump Financial, LLC | DOUBLED | $6.1M |
| FMR LLC | TRIM | $6.1M |
| FRANKLIN TEMPLETON INC | DOUBLED | $5.3M |
| Pictet Asset Management Holding SA | TRIM | $5.1M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
19 analystsPrice is below the lowest target. Median implies +58%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 13, 2026 | Citizens MAINTAIN | Market Outperform |
| Nov 11, 2026 | Citigroup MAINTAIN | Buy |
| Nov 10, 2026 | TD Cowen MAINTAIN | Buy |
| Nov 10, 2026 | Truist Securities MAINTAIN | Buy |
| Nov 10, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Oct 28, 2026 | Truist Securities MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
| 🔒 Fresh data, subscribers only Nov 13, 2026 | SELL | |
| 🔒 Fresh data, subscribers only Nov 13, 2026 | SELL | |
| 🔒 Fresh data, subscribers only Nov 13, 2026 | SELL | |
| 🔒 Fresh data, subscribers only Nov 13, 2026 | EXERCISE | |
Schayowitz Adam EVP, Head of R&D Oct 9, 2026 | EXERCISE | 37,037 sh |
Schayowitz Adam EVP, Head of R&D Oct 9, 2026 | SELL | $357.6K |
Hollywood Mark EVP & Chief Operating Officer Jul 6, 2026 | AWARD | $20.9K |
Schneider Paul R EVP, General Counsel May 13, 2026 | AWARD | 178,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $2.19 | -$0.57–$3.29 | -4.5% | $77.9M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
15 filings · 10 press releases · 3 bullish · 0 bearish · 12 neutral- NEUTRAL 8-KNov 16, 2026
Zymeworks announced a second 2026 share repurchase program authorizing up to $200 million in buybacks through 2028, following the completion of its initial $125 million program. The company expects to spend approximately $140 million under the new program, funded by existing cash and anticipated…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL PRESS RELEASENov 16, 2026
Zymeworks announced a second 2026 share repurchase program authorizing up to $200 million in buybacks through 2028, with $140 million expected to be spent. The program is funded by existing cash, near-term Roche collaboration fees ($55 million), and a potential TRELEGY milestone ($100 million).
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 144Nov 13, 2026
Paul Andrew Moore, an officer of Zymeworks, filed a Form 144 notice of intent to sell 39,741…
The filing is a routine insider sale notice for tax-related share settlement. The amount is small relative to market cap and the officer's likely total holdings. No material impact on the stock is…
- NEUTRAL 8-K/ANov 9, 2026
This 8-K/A amends the original 8-K to provide historical financial statements of Theravance…
Monitor the commercial progress of ampreloxetine, as CVR payouts depend on monetization and first commercial sales. Also watch YUPELRI profit-share cash flows, as 75% is assigned to service the…
All ZYME filing & press-release reports (25)
- 8-K reportNov 16, 2026
- PRESS-RELEASE reportNov 16, 2026
- 144 reportNov 13, 2026
- 8-K/A reportNov 9, 2026
- PRESS-RELEASE reportNov 9, 2026
- INST-CLUSTER reportNov 3, 2026
- DEFA14A reportOct 26, 2026
- DEF 14A reportOct 26, 2026
- 8-K reportOct 23, 2026
- PRESS-RELEASE reportOct 15, 2026
- 144 reportOct 9, 2026
- PRESS-RELEASE reportSep 28, 2026
- PRESS-RELEASE reportSep 23, 2026
- 8-K reportAug 25, 2026
- PRESS-RELEASE reportJul 16, 2026
- PRESS-RELEASE reportJun 29, 2026
- PRESS-RELEASE reportJun 14, 2026
- 3 reportMay 15, 2026
- PRESS-RELEASE reportApr 21, 2026
- PRESS-RELEASE reportApr 17, 2026
- PRESS-RELEASE reportApr 16, 2026
- 3 reportApr 10, 2026
- PRESS-RELEASE reportMar 17, 2026
- PRESS-RELEASE reportMar 2, 2026
- PRESS-RELEASE reportMar 2, 2026